Copper and copper proteins in Parkinson's disease

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Montes, Sergio ^a   Rivera Mancia, Susana ^a   Diaz Ruiz, Araceli ^a   Tristan Lopez, Luis ^a   Rios, Camilo ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BENEFICIAL EFFECTS; COPPER CHELATIONS; COPPER-BINDING PROTEINS; IRON ACCUMULATION; LIMITED INFORMATION; METALLOTHIONEINS; NEURODEGENERATION; PARKINSON'S DISEASE;

BRAIN; NEURODEGENERATIVE DISEASES; PROTEINS;

COPPER;

4 AMINOBUTYRIC ACID A RECEPTOR; ALPHA SYNUCLEIN; CERULOPLASMIN; COPPER; COPPER PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; FERROPORTIN; GINKGO BILOBA EXTRACT; IRON; MENKES PROTEIN; METALLOTHIONEIN; N METHYL DEXTRO ASPARTIC ACID; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN; WILSON DISEASE PROTEIN; METALLOPROTEIN;

CATALYSIS; CAUDATE NUCLEUS; CELL INCLUSION; CERULOPLASMIN BLOOD LEVEL; COPPER DEFICIENCY; FENTON REACTION; HUMAN; IMMUNOREACTIVITY; LEWY BODY; LIPID OXIDATION; MICROGLIA; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; OLIGOMERIZATION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA; SYNAPSE VESICLE; ANIMAL; METABOLISM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; COPPER; HUMANS; METALLOPROTEINS; PARKINSON DISEASE;

EID: 84893180548     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/147251     Document Type: Review

References (161)

1. Boland D. F., Stacy M., The economic and quality of life burden associated with Parkinson's disease: a focus on symptoms. The American Journal of Managed Care 2012 18 supplement 7 s168 s175
2. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models. Neuron 2003 39 6 889 909 2-s2.0-0141741347 10.1016/S0896-6273(03)00568-3 (Pubitemid 37130207)
3. Jankovic J., Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry 2008 79 4 368 376 2-s2.0-41149163183 10.1136/jnnp.2007.131045 (Pubitemid 351441488)
4. Sung V. W., Nicholas A. P., Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem. Neurologic Clinics 2013 31 supplement 3 s1 s16
5. Poletti M., de Rosa A., Bonuccelli U., Affective symptoms and cognitive functions in Parkinson's disease. Journal of the Neurological Sciences 2012 317 1-2 97 102 2-s2.0-84860265654 10.1016/j.jns.2012.02.022
6. Fahn S., Przedborski S., Rowland L. P., Pedley T. A., Parkinsonism. Merritt's Neurology 2010 New York, NY, USA Lippincott Williams & Wilkins 751 769
7. Singleton A. B., Farrer M. J., Bonifati V., The genetics of Parkinson's disease: progress and therapeutic implications. Movement Disorders 2013 28 1 14 23 10.1002/mds.25249
8. Jenner P., Oxidative stress in Parkinson's disease. Annals of Neurology 2003 53 supplement 3 S26 s36
9. Wüllner U., Klockgether T., Inflammation in Parkinson's disease. Journal of Neurology 2003 250 suppl. 1 I35 I38 (Pubitemid 36255755)
10. Schapira A. H. V., Mitochondrial dysfunction in Parkinson's disease. Cell Death and Differentiation 2007 14 7 1261 1266 2-s2.0-34250716407 10.1038/sj.cdd.4402160 (Pubitemid 46965257)
11. Rivera-Mancía S., Pérez-Neri I., Ríos C., The transition metals copper and iron in neurodegenerative diseases. Chemico-Biological Interactions 2010 186 2 184 189
12. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., Marsden C. D., Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. Journal of Neurochemistry 1989 52 6 1830 1836 2-s2.0-0024356620 (Pubitemid 19140770)
13. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K., Youdim M. B. H., Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. Journal of Neurochemistry 1989 52 2 515 520 2-s2.0-0024557734 (Pubitemid 19037617)
14. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G., Richardson R. J., Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. NeuroToxicology 1999 20 2-3 239 247 2-s2.0-0033037034
15. Willis A. W., Evanoff B. A., Lian M., Galarza A., Wegrzyn A., Schootman M., Racette B. A., Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. The American Journal of Epidemiology 2010 172 12 1357 1363 2-s2.0-79952117485
16. Mariani S., Ventriglia M., Simonelli I., Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiology of Aging 2013 34 2 632 633
17. Tórsdóttir G., Kristinsson J., Sveinbjörnsdó ttir S., Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacology and Toxicology 1999 85 5 239 243
18. Wang H. J., Wang M., Wang B., Li M., Chen H., Yu X., Zhao Y., Feng W., Chai Z., The distribution profile and oxidation states of biometals in APP transgenic mouse brain: dyshomeostasis with age and as a function of the development of Alzheimer's disease. Metallomics 2012 4 3 289 296 2-s2.0-84857774162 10.1039/c2mt00104g
19. Pall H. S., Williams A. C., Blake D. R., Lunec J., Gutteridge J. M., Hall M., Taylor A., Raised cerebrospinal-fluid copper concentration in Parkinson's disease. The Lancet 1987 2 8553 238 241 2-s2.0-0023237555 (Pubitemid 17101088)
20. Boll M. C., Alcaraz-Zubeldia M., Montes S., Rios C., Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NOx content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochemical Research 2008 33 9 1717 1723 2-s2.0-48449094910 10.1007/s11064-008-9610-3
21. Hozumi I., Hasegawa T., Honda A., Ozawa K., Hayashi Y., Hashimoto K., Yamada M., Koumura A., Sakurai T., Kimura A., Tanaka Y., Satoh M., Inuzuka T., Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. Journal of the Neurological Sciences 2011 303 1-2 95 99 2-s2.0-79952816599 10.1016/j.jns.2011.01.003
22. Loeffler D. A., LeWitt P. A., Juneau P. L., Sima A. A. F., Nguyen H., DeMaggio A. J., Brickman C. M., Brewer G. J., Dick R. D., Troyer M. D., Kanaley L., Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Research 1996 738 2 265 274 2-s2.0-0030569306 10.1016/S0006-8993(96)00782-2 (Pubitemid 26378921)
23. Prohaska J. R., Impact of copper limitation on expression and function of multicopper oxidases (ferroxidases). Advances in Nutrition 2011 2 89 95 10.3945/an.110.000208
24. Boll M. C., Sotelo J., Otero E., Alcaraz-Zubeldia M., Rios C., Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neuroscience Letters 1999 265 3 155 158 2-s2.0-0033597299 10.1016/S0304-3940(99)00221-9 (Pubitemid 29207389)
25. Ayton S., Lei P., Duce J. A., Ceruloplasmin dysfunction and therapeutic potential for Parkinson's disease. Annals of Neurology 2013 73 4 554 559
26. Hare D., Ayton S., Bush A., Lei P., A delicate balance: iron metabolism and diseases of the brain. Frontiers in Aging Neuroscience 2013 5 article 34 10.3389/fnagi.2013.00034
27. Ben-Shachar D., Youdim M. B. H., Intranigral iron injection induces behavioral and biochemical "Parkinsonism" in rats. Journal of Neurochemistry 1991 57 6 2133 2135 2-s2.0-0025824668 (Pubitemid 21922868)
28. Spencer W. A., Jeyabalan J., Kichambre S., Gupta R. C., Oxidatively generated DNA damage after Cu(II) catalysis of dopamine and related catecholamine neurotransmitters and neurotoxins: role of reactive oxygen species. Free Radical Biology and Medicine 2011 50 1 139 147 2-s2.0-78650694707 10.1016/j.freeradbiomed.2010.10.693
29. Ozcelik D., Uzun H., Copper intoxication; antioxidant defenses and oxidative damage in rat brain. Biological Trace Element Research 2009 127 1 45 52 2-s2.0-64749089732 10.1007/s12011-008-8219-3
30. 2+) induces degeneration of dopaminergic neurons in the nigrostriatal system of rats. Neuroscience Bulletin 2008 24 2 73 78 2-s2.0-44349129732 10.1007/s12264-008- 0073-y (Pubitemid 351738281)
31. Olanow C. W., Brundin P., Parkinson's disease and α synuclein: is Parkinson's disease a prion-like disorder? Movement Disorders 2013 28 1 31 40
32. Uversky V. N., Li J., Fink A. L., Metal-triggered structural transformations, aggregation, and fibrillation of human α -synuclein: a possible molecular link between Parkinson's disease and heavy metal exposure. The Journal of Biological Chemistry 2001 276 47 44284 44296 2-s2.0-0035941201 10.1074/jbc.M105343200
33. Paik S. R., Shin H. J., Lee J. H., Chang C., Kim J., Copper(II)-induced self-oligomerization of α -synuclein. Biochemical Journal 1999 340 part 3 821 828 2-s2.0-0033564726 10.1042/0264-6021:3400821 (Pubitemid 29312882)
34. Wright J. A., Wang X., Brown D. R., Unique copper-induced oligomers mediate α -synuclein toxicity. FASEB Journal 2009 23 8 2384 2393 2-s2.0-68849102707 10.1096/fj.09-130039
35. de Romaña D. L., Olivares M., Uauy R., Araya M., Risks and benefits of copper in light of new insights of copper homeostasis. Journal of Trace Elements in Medicine and Biology 2011 25 1 3 13 2-s2.0-79952701447 10.1016/j.jtemb.2010.11.004
36. Gaier E. D., Eipper B. A., Mains R. E., Copper signaling in the mammalian nervous system: synaptic effects. Journal of Neuroscience Research 2013 91 1 2 19
37. Harris Z. L., Gitlin J. D., Genetic and molecular basis for copper toxicity. The American Journal of Clinical Nutrition 1996 63 5 836S 841S 2-s2.0-15844384254 (Pubitemid 26126606)
38. El-Youssef M., Wilson disease. Mayo Clinic Proceedings 2003 78 9 1126 1136 2-s2.0-0041356966 (Pubitemid 37055657)
39. Tapiero H., Townsend D. M., Tew K. D., Trace elements in human physiology and pathology. Copper. Biomedicine and Pharmacotherapy 2003 57 9 386 398 2-s2.0-0344688221 10.1016/S0753-3322(03)00012-X (Pubitemid 37494714)
40. Schlief M. L., Craig A. M., Gitlin J. D., NMDA receptor activation mediates copper homeostasis in hippocampal neurons. Journal of Neuroscience 2005 25 1 239 246 2-s2.0-12144257164 10.1523/JNEUROSCI.3699-04.2005 (Pubitemid 40110786)
41. Saito T., Itoh T., Fujimura M., Saito K., Age-dependent and region-specific differences in the distribution of trace elements in 7 brain regions of Long-Evans Cinnamon (LEC) rats with hereditary abnormal copper metabolism. Brain Research 1995 695 2 240 244 2-s2.0-0028806434 10.1016/0006-8993(95)00819-C
42. Trombley P. Q., Shepherd G. M., Differential modulation by zinc and copper of amino acid receptors from rat olfactory bulb neurons. Journal of Neurophysiology 1996 76 4 2536 2546 2-s2.0-0029910647 (Pubitemid 26346427)
43. Vlachová V., Zemková H., Vyklický L. Jr., Copper modulation of NMDA responses in mouse and rat cultured hippocampal neurons. European Journal of Neuroscience 1996 8 11 2257 2264 2-s2.0-0029964789 10.1111/j.1460-9568.1996.tb01189.x (Pubitemid 26387887)
44. Weiser T., Wienrich M., The effects of copper ions on glutamate receptors in cultured rat cortical neurons. Brain Research 1996 742 1-2 211 218 2-s2.0-0030566645 10.1016/S0006-8993(96)01009-8 (Pubitemid 27016025)
45. Salazar-Weber N. L., Smith J. P., Copper inhibits NMDA receptor-independent LTP and modulates the paired-pulse ratio after LTP in mouse hippocampal slices. International Journal of Alzheimer's Disease 2011 2011 10 2-s2.0-84855288786 10.4061/2011/864753 864753
46. Peters C., Muñoz B., Sepúlveda F. J., Biphasic effects of copper on neurotransmission in rat hippocampal neurons. Journal of Neurochemistry 2011 119 1 78 88
47. Kardos J., Kovács I., Hajós F., Kalman M., Simonyi M., Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability. Neuroscience Letters 1989 103 2 139 144 2-s2.0-0024362166 (Pubitemid 19201242)
48. 2+ sensitivity of α β 3 γ 2L GABAA receptors. Molecular Pharmacology 2003 64 5 1145 1152 2-s2.0-0142148095 10.1124/mol.64.5.1145 (Pubitemid 37310747)
49. McGee T. P., Houston C. M., Brickley S. G., Copper block of extrasynaptic GABAA receptors in the mature cerebellum and striatum. Journal of Neuroscience 2013 33 33 13431 13435
50. Horning M. S., Trombley P. Q., Zinc and copper influence excitability of rat olfactory bulb neurons by multiple mechanisms. Journal of Neurophysiology 2001 86 4 1652 1660 2-s2.0-0034786489 (Pubitemid 32953216)
51. Spillantini M. G., Schmidt M. L., Lee V. M.-., Trojanowski J. Q., Jakes R., Goedert M., α -synuclein in Lewy bodies. Nature 1997 388 6645 839 840 2-s2.0-0030882856 10.1038/42166 (Pubitemid 27377048)
52. El-Agnaf O. M. A., Salem S. A., Paleologou K. E., Curran M. D., Gibson M. J., Court J. A., Schlossmacher M. G., Allsop D., Detection of oligomeric forms of α -synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB Journal 2006 20 3 419 425 2-s2.0-33645833848 10.1096/fj.03-1449com (Pubitemid 44933318)
53. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M., Full length α -synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neuroscience Letters 2000 287 1 65 67 2-s2.0-0034674376 10.1016/S0304-3940(00)01153-8 (Pubitemid 30332379)
54. Singleton A. B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M. R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K., α -synuclein locus triplication causes Parkinson's disease. Science 2003 302 5646 841 2-s2.0-0242300619 10.1126/science.1090278 (Pubitemid 37339619)
55. McNaught K. S. P., Olanow C. W., Halliwell B., Isacson O., Jenner P., Failure of the ubiquitin-proteasome system in Parkinson's disease. Nature Reviews Neuroscience 2001 2 8 589 594 2-s2.0-0035430788 10.1038/35086067 (Pubitemid 33679832)
56. Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E., Sawa A., Dawson V. L., Dawson T. M., Ross C. A., Inducible expression of mutant α -synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics 2001 10 9 919 926 2-s2.0-0035870881 (Pubitemid 32401408)
57. Rasia R. M., Bertoncini C. W., Marsh D., Hoyer W., Cherny D., Zweckstetter M., Griesinger C., Jovin T. M., Fernández C. O., Structural characterization of copper(II) binding to α -synuclein: insights into the bioinorganic chemistry of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2005 102 12 4294 4299 2-s2.0-15444373250 10.1073/pnas.0407881102 (Pubitemid 40397105)
58. 2+ complex and their effects on neuronal cell viability. Biochemistry 2010 49 37 8134 8142 2-s2.0-77956571912 10.1021/bi1010909
59. Davies P., Moualla D., Brown D. R., α -synuclein is a cellular ferrireductase. PLoS ONE 2011 6 1 2-s2.0-79251572323 10.1371/journal.pone. 0015814 e15814
60. Healy J., Tipton K., Ceruloplasmin and what it might do. Journal of Neural Transmission 2007 114 6 777 781 2-s2.0-34250903216 10.1007/s00702-007- 0687-7 (Pubitemid 46980484)
61. Sato M., Gitlin J. D., Mechanisms of copper incorporation during the biosynthesis of human ceruloplasmin. The Journal of Biological Chemistry 1991 266 8 5128 5134 2-s2.0-0025729544 (Pubitemid 21909468)
62. Vashchenko G., MacGillivray R. T., Multi-copper oxidases and human iron metabolism. Nutrients 2013 5 7 2289 2313
63. Patel B. N., David S., A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. The Journal of Biological Chemistry 1997 272 32 20185 20190 2-s2.0-0030856558 10.1074/jbc.272.32.20185 (Pubitemid 27340128)
64. Yoshida K., Furihata K., Takeda S., Nakamura A., Yamamoto K., Morita H., Hiyamuta S., Ikeda S., Shimizu N., Yanagisawa N., A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nature Genetics 1995 9 3 267 272 2-s2.0-0028895749
65. Martin W. R. W., Wieler M., Gee M., Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008 70 16, part 2 1411 1417 2-s2.0-42049123661 10.1212/01.wnl.0000286384.31050.b5 (Pubitemid 351521933)
66. Berg D., Siefker C., Becker G., Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. Journal of Neurology 2001 248 8 684 689 2-s2.0-0034935922 10.1007/s004150170114 (Pubitemid 32695865)
67. Zecca L., Berg D., Arzberger T., Ruprecht P., Rausch W. D., Musicco M., Tampellini D., Riederer P., Gerlach M., Becker G., In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Movement Disorders 2005 20 10 1278 1285 2-s2.0-27844547163 10.1002/mds.20550 (Pubitemid 41645902)
68. Martínez-Hernández R., Montes S., Higuera-Calleja J., Yescas P., Boll M., Diaz-Ruiz A., Rios C., Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study. Neurochemical Research 2011 36 11 2111 2115 2-s2.0-80054992416 10.1007/s11064-011-0535-x
69. Jin L., Wang J., Zhao L., Jin H., Fei G., Zhang Y., Zeng M., Zhong C., Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011 134 1 50 58 2-s2.0-78650695967 10.1093/brain/awq319
70. Bharucha K. J., Friedman J. K., Vincent A. S., Ross E. D., Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. Journal of Neurology 2008 255 12 1957 1962 2-s2.0-67349173208 10.1007/s00415-009-0063-7
71. Olivieri S., Conti A., Iannaccone S., Cannistraci C. V., Campanella A., Barbariga M., Codazzi F., Pelizzoni I., Magnani G., Pesca M., Franciotta D., Cappa S. F., Alessio M., Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. Journal of Neuroscience 2011 31 50 18568 18577 2-s2.0-83455177604 10.1523/JNEUROSCI.3768-11.2011
72. Hochstrasser H., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., Zeiler B., Bornemann A., Pahnke J., Becker G., Riess O., Berg D., Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004 63 10 1912 1917 2-s2.0-5444246509 (Pubitemid 39532390)
73. McCord J. M., Fridovich I., Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). The Journal of Biological Chemistry 1969 244 22 6049 6055 2-s2.0-0014691242
74. Cohen G., The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. Journal of Neural Transmission. Supplementa 1983 19 89 103 2-s2.0-0021009820
75. Marklund S. L., Human copper-containing superoxide dismutase of high molecular weight. Proceedings of the National Academy of Sciences of the United States of America 1982 79 24 7634 7638 2-s2.0-0006157248 (Pubitemid 13173159)
76. Przedborski S., Kostic V., Jackson-Lewis V., Naini A. B., Simonetti S., Fahn S., Carlson E., Epstein C. J., Cadet J. L., Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity. Journal of Neuroscience 1992 12 5 1658 1667 2-s2.0-0026583465
77. Nakao N., Frodl E. M., Widner H., Carlson E., Eggerding F. A., Epstein C. J., Brundin P., Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Medicine 1995 1 3 226 231 2-s2.0-0028899401
78. Polazzi E., Mengoni I., Caprini M., Copper-zinc superoxide dismutase (SOD1) is released by microglial cells and confers neuroprotection against 6-OHDA neurotoxicity. Neurosignals 2013 21 1-2 112 128
79. Takano K., Tanaka N., Kawabe K., Extracellular superoxide dismutase induced by dopamine in cultured astrocytes. Neurochemical Research 2013 38 1 32 41
80. Wang Z., Liu J., Chen S., Wang Y., Cao L., Zhang Y., Kang W., Li H., Gui Y., Chen S., Ding J., DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Annals of Neurology 2011 70 4 591 599 2-s2.0-84855409709 10.1002/ana.22514
81. Earhart G. M., Falvo M. J., Parkinson's disease and exercise. Comprehensive Physiology 2013 3 2 833 848
82. Tuon T., Valvassori S. S., Lopes-Borges J., Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson's disease. Neuroscience 2012 227 305 312
83. Ihara Y., Chuda D., Kuroda S., Hayabara T., Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. Journal of the Neurological Sciences 1999 170 2 90 95 2-s2.0-0032748301 10.1016/S0022-510X(99)00192-6 (Pubitemid 29528530)
84. Venkateshappa C., Harish G., Mythri R. B., Mahadevan A., Srinivas Bharath M. M., Shankar S. K., Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochemical Research 2012 37 2 358 369 2-s2.0-84856372105 10.1007/s11064-011-0619-7
85. Stankovic R. K., Chung R. S., Penkowa M., Metallothioneins I and II: neuroprotective significance during CNS pathology. International Journal of Biochemistry and Cell Biology 2007 39 3 484 489 2-s2.0-33846260825 10.1016/j.biocel.2006.09.010 (Pubitemid 46096789)
86. Vašák M., Meloni G., Chemistry and biology of mammalian metallothioneins. Journal of Biological Inorganic Chemistry 2011 16 7 1067 1078 2-s2.0-80755140125 10.1007/s00775-011-0799-2
87. Penkowa M., Cáceres M., Borup R., Nielsen F. C., Poulsen C. B., Quintana A., Molinero A., Carrasco J., Florit S., Giralt M., Hidalgo J., Novel roles for metallothionein-I + II (MT-I + II) in defense responses, neurogenesis, and tissue restoration after traumatic brain injury: insights from global gene expression profiling in wild-type and MT-I + II knockout mice. Journal of Neuroscience Research 2006 84 7 1452 1474 2-s2.0-33750600258 10.1002/jnr.21043 (Pubitemid 44683139)
88. Reinecke F., Levanets O., Olivier Y., Louw R., Semete B., Grobler A., Hidalgo J., Smeitink J., Olckers A., Van Der Westhuizen F. H., Metallothionein isoform 2A expression is inducible and protects against ROS-mediated cell death in rotenone-treated HeLa cells. Biochemical Journal 2006 395 2 405 415 2-s2.0-33645767663 10.1042/BJ20051253
89. Michael G. J., Esmailzadeh S., Moran L. B., Christian L., Pearce R. K. B., Graeber M. B., Up-regulation of metallothionein gene expression in Parkinsonian astrocytes. Neurogenetics 2011 12 4 295 305 2-s2.0-84855289046 10.1007/s10048-011-0294-5
90. Dhanasekaran M., Albano C. B., Pellet L., Karuppagounder S. S., Uthayathas S., Suppiramaniam V., Brown-Borg H., Ebadi M., Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1, 2,3,6- tetrahydropyridine-induced neurotoxicity. Neurochemical Research 2008 33 6 980 984 2-s2.0-42149129574 10.1007/s11064-007-9468-9
91. Ebadi M., Sharma S., Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Experimental Biology and Medicine 2006 231 9 1576 1583 2-s2.0-33749610125 (Pubitemid 44547853)
92. 7-metallothionein-3. Free Radical Biology and Medicine 2011 50 11 1471 1479 2-s2.0-79955630377 10.1016/j.freeradbiomed.2011.02.003
93. White A. R., Reyes R., Mercer J. F. B., Camakaris J., Zheng H., Bush A. I., Multhaup G., Beyreuther K., Masters C. L., Cappai R., Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Research 1999 842 2 439 444 2-s2.0-0032830357 10.1016/S0006-8993(99)01861-2 (Pubitemid 29475178)
94. Maynard C. J., Cappai R., Volitakis I., Cherny R. A., White A. R., Beyreuther K., Masters C. L., Bush A. I., Li Q., Overexpression of Alzheimer's disease amyloid- β opposes the age-dependent elevations of brain copper and iron. The Journal of Biological Chemistry 2002 277 47 44670 44676 2-s2.0-0037160028 10.1074/jbc.M204379200 (Pubitemid 36159056)
95. Duce J. A., Tsatsanis A., Cater M. A., James S. A., Robb E., Wikhe K., Leong S. L., Perez K., Johanssen T., Greenough M. A., Cho H., Galatis D., Moir R. D., Masters C. L., McLean C., Tanzi R. E., Cappai R., Barnham K. J., Ciccotosto G. D., Rogers J. T., Bush A. I., Iron-export ferroxidase activity of β -amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010 142 6 857 867 2-s2.0-77956647381 10.1016/j.cell.2010.08.014
96. Björkblom B., Adilbayeva A., Maple-Grødem J., Parkinson's disease protein DJ-1 binds metals and protects against metal-induced cytotoxicity. The Journal of Biological Chemistry 2013 288 31 22809 22820
97. Kim R. H., Smith P. D., Aleyasin H., Hayley S., Mount M. P., Pownall S., Wakeham A., You-Ten A. J., Kalia S. K., Horne P., Westaway D., Lozano A. M., Anisman H., Park D. S., Mak T. W., Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2005 102 14 5215 5220 2-s2.0-20144389422 10.1073/pnas.0501282102
98. Greenough M. A., Volitakis I., Li Q. X., Laughton K., Evin G., Ho M., Dalziel A. H., Camakaris J., Bush A. I., Presenilins promote the cellular uptake of copper and zinc and maintain copper chaperone of SOD1-dependent copper/zinc superoxide dismutase activity. The Journal of Biological Chemistry 2011 286 11 9776 9786 2-s2.0-79953167471 10.1074/jbc.M110.163964
99. Southon A., Greenough M. A., Ganio G., Presenilin promotes dietary copper uptake. PLoS ONE 2013 8 5 e62811
100. Que E. L., Domaille D. W., Chang C. J., Metals in neurobiology: probing their chemistry and biology with molecular imaging. Chemical Reviews 2008 108 5 1517 1549 2-s2.0-44849102395 10.1021/cr078203u (Pubitemid 351796396)
101. Brown D. R., Qin K. F., Herms J. W., Madlung A., Manson J., Strome R., Fraser P. E., Kruck T., von Bohlen A., Schulz-Schaeffer W., Giese A., Westaway D., Kretzschmar H., The cellular prion protein binds copperin vivo. Nature 1997 390 6661 684 687 2-s2.0-0031444294 10.1038/37783 (Pubitemid 28016355)
102. Telianidis J., Hung Y. H., Materia S., Fontaine S. L., Role of the P-type ATPases, ATP7A and ATP7B in brain copper homeostasis. Frontiers in Aging Neuroscience 2013 5 article 44
103. Huffman D. L., O'Halloran T. V., Function, structure, and mechanism of intracellular copper trafficking proteins. Annual Review of Biochemistry 2001 70 677 701 2-s2.0-0034913058 10.1146/annurev.biochem.70.1.677 (Pubitemid 32662222)
104. Linder M. C., Biochemistry of Copper 1991 New York, NY, USA Plenum Press
105. Choi B. S., Zheng W., Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Research 2009 1248 14 21 2-s2.0-57649158930 10.1016/j.brainres.2008.10.056
106. Meyer L. A., Durley A. P., Prohaska J. R., Harris Z. L., Copper transport and metabolism are normal in aceruloplasminemic mice. The Journal of Biological Chemistry 2001 276 39 36857 36861 2-s2.0-0035965212 10.1074/jbc.M105361200
107. Monnot A. D., Behl M., Ho S., Zheng W., Regulation of brain copper homeostasis by the brain barrier systems: effects of Fe-overload and Fe-deficiency. Toxicology and Applied Pharmacology 2011 256 3 249 257 2-s2.0-80855143780 10.1016/j.taap.2011.02.003
108. Penkowa M., Nielsen H., Hidalgo J., Distribution of metallothionein I + II and vesicular zinc in the developing central nervous system: correlative study in the rat. Journal of Comparative Neurology 1999 412 2 303 318 (Pubitemid 29395367)
109. Skjørringe T., Møller L. B., Moos T., Impairment of interrelated iron- and copper homeostatic mechanisms in brain contributes to the pathogenesis of neurodegenerative disorders. Frontiers in Pharmacology 2012 3 article 169
110. Zheng G., Chen J., Zheng W., Relative contribution of CTR1 and DMT1 in copper transport by the blood-CSF barrier: implication in manganese-induced neurotoxicity. Toxicology and Applied Pharmacology 2012 260 3 285 293 2-s2.0-84859988715 10.1016/j.taap.2012.03.006
111. Gaggelli E., Kozlowski H., Valensin D., Valensin G., Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chemical Reviews 2006 106 6 1995 2044 2-s2.0-33745726690 10.1021/cr040410w
112. Kuo Y., Gybina A. A., Pyatskowit J. W., Gitschier J., Prohaska J. R., Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. Journal of Nutrition 2006 136 1 21 26 2-s2.0-31544454133 (Pubitemid 43156479)
113. Zheng W., Monnot A. D., Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacology and Therapeutics 2012 133 2 177 188 2-s2.0-84856489978 10.1016/j.pharmthera.2011.10.006
114. Lutsenko S., Bhattacharjee A., Hubbard A. L., Copper handling machinery of the brain. Metallomics 2010 2 9 596 608 2-s2.0-77956330693 10.1039/c0mt00006j
115. Davies K. M., Hare D. J., Cottam V., Localization of copper and copper transporters in the human brain. Metallomics: An Integrated Biometal Science 2013 5 1 43 51
116. Bohic S., Murphy K., Paulus W., Cloetens P., Salomé M., Susini J., Double K., Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Analytical Chemistry 2008 80 24 9557 9566 2-s2.0-58149127699 10.1021/ac801817k
117. Petris M. J., Smith K., Lee J., Thiele D. J., Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. The Journal of Biological Chemistry 2003 278 11 9639 9646 2-s2.0-0038439210 10.1074/jbc.M209455200 (Pubitemid 36800460)
118. Davies K., Bohic S., Ortega R., Copper pathology in the vulnerable substantia nigra in Parkinson's disease. Movement Disorders 2013 28 supplement 1, article 1024
119. Mackenzie N. C., Brito M., Reyes A. E., Allende M. L., Cloning, expression pattern and essentiality of the high-affinity copper transporter 1 (ctr1) gene in zebrafish. Gene 2004 328 1-2 113 120 2-s2.0-1542500529 10.1016/j.gene.2003.11.019 (Pubitemid 38352887)
120. Tanchou V., Gas F., Urvoas A., Cougouluègne F., Ruat S., Averseng O., Quéméneur E., Copper-mediated homo-dimerisation for the HAH1 metallochaperone. Biochemical and Biophysical Research Communications 2004 325 2 388 394 2-s2.0-7644220114 10.1016/j.bbrc.2004.10.048 (Pubitemid 39458007)
121. Klomp L. W., Lin S. J., Yuan D. S., Klausner R. D., Culotta V. C., Gitlin J. D., Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. The Journal of Biological Chemistry 1997 272 14 9221 9226 2-s2.0-0030898098 10.1074/jbc.272.14.9221 (Pubitemid 27154931)
122. Naeve G. S., Vana A. M., Eggold J. R., Kelner G. S., Maki R., Desouza E. B., Foster A. C., Expression profile of the copper homeostasis gene, rAtox1, in the rat brain. Neuroscience 1999 93 3 1179 1187 2-s2.0-0032811620 10.1016/S0306-4522(99)00175-X (Pubitemid 29341665)
123. Hamza I., Prohaska J., Gitlin J. D., Essential role for Atox1 in the copper-mediated intracellular trafficking of the Menkes ATPase. Proceedings of the National Academy of Sciences of the United States of America 2003 100 3 1215 1220 2-s2.0-0037417798 10.1073/pnas.0336230100 (Pubitemid 36183982)
124. Liu Y. Y., Nagpure B. V., Wong P. T. H., Bian J. S., Hydrogen sulfide protects SH-SY5Y neuronal cells against d-galactose induced cell injury by suppression of advanced glycation end products formation and oxidative stress. Neurochemistry International 2013 62 5 603 609
125. Walker J. M., Tsivkovskii R., Lutsenko S., Metallochaperone Atox1 transfers copper to the NH2-terminal domain of the Wilson's disease protein and regulates its catalytic activity. The Journal of Biological Chemistry 2002 277 31 27953 27959 2-s2.0-0037008692 10.1074/jbc.M203845200 (Pubitemid 34966743)
126. Hamza I., Faisst A., Prohaska J., Chen J., Gruss P., Gitlin J. D., The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis. Proceedings of the National Academy of Sciences of the United States of America 2001 98 12 6848 6852 2-s2.0-0035811058 10.1073/pnas.111058498 (Pubitemid 32538305)
127. Itoh S., Ozumi K., Kim H. W., Nakagawa O., McKinney R. D., Folz R. J., Zelko I. N., Ushio-Fukai M., Fukai T., Novel mechanism for regulation of extracellular SOD transcription and activity by copper: role of antioxidant-1. Free Radical Biology and Medicine 2009 46 1 95 104 2-s2.0-57649092644 10.1016/j.freeradbiomed.2008.09.039
128. Iwase T., Nishimura M., Sugimura H., Igarashi H., Ozawa F., Shinmura K., Suzuki M., Tanaka M., Kino I., Localization of Menkes gene expression in the mouse brain; its association with neurological manifestations in Menkes model mice. Acta Neuropathologica 1996 91 5 482 488 2-s2.0-0029930329 10.1007/s004010050455 (Pubitemid 26133659)
129. Kaler S. G., Schwartz J. P., Expression of the Menkes disease homolog in rodent neuroglial cells. Neuroscience Research Communications 1998 23 1 61 66 10.1002/(SICI)1520-6769(199807/08)23:1<61::AID-NRC7>3.0.CO;2-J (Pubitemid 28419718)
130. Qian Y., Tiffany-Castiglioni E., Welsh J., Harris E. D., Copper efflux from murine microvascular cells requires expression of the Menkes disease CU-ATPase. Journal of Nutrition 1998 128 8 1276 1282 2-s2.0-0031829282 (Pubitemid 28361417)
131. Petris M. J., Mercer J. F. B., Culvenor J. G., Lockhart P., Gleeson P. A., Camakaris J., Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. EMBO Journal 1996 15 22 6084 6095 2-s2.0-0029909937 (Pubitemid 26397881)
132. Roelofsen H., Wolters H., van Luyn M. J. A., Miura N., Kuipers F., Vonk R. J., Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. Gastroenterology 2000 119 3 782 793 2-s2.0-0033862878
133. Barnes N., Tsivkovskii R., Tsivkovskaia N., Lutsenko S., The copper-transporting ATPases, Menkes and Wilson disease proteins, have distinct roles in adult and developing cerebellum. The Journal of Biological Chemistry 2005 280 10 9640 9645 2-s2.0-15744392287 10.1074/jbc.M413840200 (Pubitemid 40409661)
134. Yasmeen S., Lund K., de Paepe A., Occipital horn syndrome and classical Menkes syndrome caused by deep intronic mutations, leading to the activation of ATP7A pseudo-exon. European Journal of Human Genetics 2013 10.1038/ejhg.2013.191
135. Weiss K. H., Runz H., Noe B., Gotthardt D. N., Merle U., Ferenci P., Stremmel W., Füllekrug J., Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. Journal of Inherited Metabolic Disease 2010 33 3, supplement 233 240 2-s2.0-77952761688 10.1007/s10545-010-9123-5
136. Sechi G., Antonio-Cocco G., Errigo A., Deiana L., Rosati G., Agnetti V., Stephen Paulus K., Mario Pes G., Three sisters with very-late-onset major depression and parkinsonism. Parkinsonism and Related Disorders 2007 13 2 122 125 2-s2.0-33847253957 10.1016/j.parkreldis.2006.03.009 (Pubitemid 46329514)
137. Bull P. C., Thomas G. R., Rommens J. M., Forbes J. R., Cox D. W., The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genetics 1993 5 4 327 337 2-s2.0-0027452091 10.1038/ng1293-327 (Pubitemid 23351302)
138. Johnson S., Is Parkinson's disease the heterozygote form of Wilson's disease: PD = 1/2 WD? Medical Hypotheses 2001 56 2 171 173 2-s2.0-0035097871 10.1054/mehy.2000.1134 (Pubitemid 32202623)
139. Lenartowicz M., Wieczerzak K., Krzeptowski W., Dobosz P., Grzmil P., Starzyński R., Lipiński P., Developmental changes in the expression of the Atp7a gene in the liver of mice during the postnatal period. Journal of Experimental Zoology A 2010 313 4 209 217 2-s2.0-77951064105 10.1002/jez.586
140. Terada K., Nakako T., Yang X., Iida M., Aiba N., Minamiya Y., Nakai M., Sakaki T., Miura N., Sugiyama T., Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adenovirus bearing WND cDNA. The Journal of Biological Chemistry 1998 273 3 1815 1820 2-s2.0-17144458094 10.1074/jbc.273.3.1815 (Pubitemid 28133716)
141. Gruenheid S., Cellier M., Vidal S., Gros P., Identification and characterization of a second mouse Nramp gene. Genomics 1995 25 2 514 525 2-s2.0-0028962892 10.1016/0888-7543(95)80053-O
142. Gunshin H., Mackenzie B., Berger U. V., Gunshin Y., Romero M. F., Boron W. F., Nussberger S., Gollan J. L., Hediger M. A., Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997 388 6641 482 488 2-s2.0-0030755366 10.1038/41343 (Pubitemid 27328927)
143. Wang X., Li G. J., Zheng W., Upregulation of DMT1 expression in choroidal epithelia of the blood-CSF barrier following manganese exposure in vitro. Brain Research 2006 1097 1 1 10 2-s2.0-33745907562 10.1016/j.brainres.2006.04.046 (Pubitemid 44041282)
144. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L. M., Nuñez M. T., Garrick M. D., Raisman-Vozari R., Hirsch E. C., Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2008 105 47 18578 18583 2-s2.0-57449092273 10.1073/pnas.0804373105
145. He Q., Du T., Yu X., DMT1 polymorphism and risk of Parkinson's disease. Neuroscience Letters 2011 501 3 128 131
146. Hung L. W., Villemagne V. L., Cheng L., The hypoxia imaging agent CuII (atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. Journal of Experimental Medicine 2012 209 4 837 854
147. Obeso J. A., Rodriguez-Oroz M. C., Goetz C. G., Marin C., Kordower J. H., Rodriguez M., Hirsch E. C., Farrer M., Schapira A. H. V., Halliday G., Missing pieces in the Parkinson's disease puzzle. Nature Medicine 2010 16 6 653 661 2-s2.0-77953229747 10.1038/nm.2165
148. Rubio-Osornio M., Montes S., Pérez-Severiano F., Aguilera P., Floriano-Sánchez E., Monroy-Noyola A., Rubio C., Ríos C., Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats. Neurochemistry International 2009 54 7 447 451 2-s2.0-63149142549 10.1016/j.neuint.2009.01.019
149. Rubio-Osornio M., Montes S., Heras-Romero Y., Induction of ferroxidase enzymatic activity by copper reduces MPP(+)-evoked neurotoxicity in rats. Neuroscience Research 2013 75 3 250 255 10.1016/j.neures.2012.12.003
150. Rojas P., Rojas C., Ebadi M., Montes S., Monroy-Noyola A., Serrano-García N., EGb761 pretreatment reduces monoamine oxidase activity in mouse corpus striatum during 1-methyl-4-phenylpyridinium neurotoxicity. Neurochemical Research 2004 29 7 1417 1423 2-s2.0-3442881920 10.1023/B:NERE.0000026406.64547.93 (Pubitemid 39011329)
151. Rojas P., Montes S., Serrano-García N., Rojas-Castañeda J., Effect of EGb761 supplementation on the content of copper in mouse brain in an animal model of Parkinson's disease. Nutrition 2009 25 4 482 485 2-s2.0-60749132461 10.1016/j.nut.2008.10.013
152. Mandel S., Weinreb O., Amit T., Youdim M. B. H., Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin- 3-gallate: implications for neurodegenerative diseases. Journal of Neurochemistry 2004 88 6 1555 1569 2-s2.0-1642382889 (Pubitemid 38366932)
153. Youdim M. B. H., Grünblatt E., Mandel S., The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. Journal of Neural Transmission 2007 114 2 205 209 2-s2.0-33846438299 10.1007/s00702-006-0499-1 (Pubitemid 46147157)
154. Rios C., Alvarez-Vega R., Rojas P., Depletion of copper and manganese in brain after MPTP treatment of mice. Pharmacology and Toxicology 1995 76 6 348 352 2-s2.0-0029063832
155. Arredondo M., Núñez M. T., Iron and copper metabolism. Molecular Aspects of Medicine 2005 26 4-5 313 327 (Pubitemid 41225355)
156. Aigner E., Theurl I., Haufe H., Seifert M., Hohla F., Scharinger L., Stickel F., Mourlane F., Weiss G., Datz C., Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008 135 2 680.e1 688.e1 2-s2.0-48549094554 10.1053/j.gastro.2008.04.007
157. Crowe A., Morgan E. H., Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the two metals. Journal of Nutrition 1996 126 1 183 194 2-s2.0-0030070042 (Pubitemid 26030648)
158. Henkin R. I., Potolicchio S. J., Levy L. M., Moharram R., Velicu I., Martin B. M., Carbonic anhydrase I, II, and VI, blood plasma, erythrocyte and saliva zinc and copper increase after repetitive transcranial magnetic stimulation. The American Journal of the Medical Sciences 2010 339 3 249 257 2-s2.0-77949431798 10.1097/MAJ.0b013e3181cda0e3
159. Khedr E. M., Rothwell J. C., Shawky O. A., Ahmed M. A., Foly K N., Hamdy A., Dopamine levels after repetitive transcranial magnetic stimulation of motor cortex in patients with Parkinson's disease: preliminary results. Movement Disorders 2007 22 7 1046 1050 2-s2.0-34347250117 10.1002/mds.21460 (Pubitemid 46999309)
160. Randhawa B. K., Farley B. G., Boyd L. A., Repetitive transcranial magnetic stimulation improves handwriting in Parkinson's disease. Parkinson's Disease 2013 2013 9 751925 10.1155/2013/751925
161. Strafella A. P., Ko J. H., Grant J., Fraraccio M., Monchi O., Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study. European Journal of Neuroscience 2005 22 11 2946 2952 2-s2.0-29144478738 10.1111/j.1460-9568.2005.04476.x (Pubitemid 41811290)